Dizal Pharmaceutical(SH:688192) Xin Lang Cai Jing·2025-08-28 01:34Core Viewpoint - Dize Pharmaceutical experienced a decline of 4.31% in stock price on August 27, with a trading volume of 423 million yuan, indicating potential market volatility and investor sentiment concerns [1] Financing Summary - On August 27, Dize Pharmaceutical had a financing buy-in amount of 23.54 million yuan and a financing repayment of 35.11 million yuan, resulting in a net financing outflow of 11.57 million yuan [1] - The total financing and securities lending balance for Dize Pharmaceutical reached 151 million yuan, with the financing balance accounting for 0.48% of the circulating market value, indicating a high level compared to the past year [1] - The company had a securities lending repayment of 400 shares and a securities lending sell-out of 200 shares, with a sell-out amount of 15,100 yuan, and a securities lending balance of 1.13 million yuan, also reflecting a high level compared to the past year [1] Company Profile - Dize Pharmaceutical, established on October 27, 2017, and listed on December 10, 2021, is located in Wuxi, Jiangsu Province, focusing on the research and industrialization of innovative drugs, with 100% of its main business revenue derived from drug sales [1] Financial Performance - As of June 30, 2025, Dize Pharmaceutical reported a revenue of 355 million yuan, representing a year-on-year growth of 74.40%, while the net profit attributable to the parent company was -37.7 million yuan, a decrease of 9.46% year-on-year [2] - The number of shareholders decreased by 3.45% to 8,386, while the average circulating shares per person increased by 3.58% to 22,265 shares [2] Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included new entrants such as Yongying Pharmaceutical Innovation Mixed Fund A and Zhongou Medical Health Mixed Fund A, while some existing shareholders like Ping An Medical Health Mixed Fund A exited the top ten list [2]